Outcome of Innate Pharma's 2022 Annual General Meeting
Innate Pharma to participate in upcoming investor conferences
Innate Pharma reports First Quarter 2022 financial results and business update
Number of shares and voting rights of Innate Pharma as of May 1, 2022
Innate Pharma establishes an At-The-Market ("ATM") program on Nasdaq
Innate Pharma announces conference call and webcast for Q1 2022 Business Update
First patient dosed in monalizumab Phase 3 lung cancer clinical trial triggers $50M payment from AstraZeneca
Innate Pharma to hold its Annual General Meeting of shareholders on May 20, 2022
Innate Pharma files its 2021 Universal Registration Document (Document d'enregistrement universel) and 2021 Annual Report on Form 20-F
Innate Pharma reports Full Year 2021 financial results and business update
